Live Update from ESMO: Medivir

2024-09-16

11:45-12:45

Live broadcast at redeye.se/events

English language

2024-09-16

11:45-12:45

Live broadcast at redeye.se/events

English language

Live broadcast at redeye.se/events

English language

Live broadcast at redeye.se/events

English language

Medivir presents mature clinical data for fostrox + Lenvima in liver cancer (HCC) at the European Society for Medical Oncology (ESMO) Congress, Barcelona on Sep 16th 2024.
 
Follow a live broadcast presentation and interview afterward from Barcelona, allowing participants to send in questions beforehand.
 
Introduction – Fostrox, designed to target liver cancer
Dr Pia Baumann, Chief Medical Officer, Medivir AB
 
Fostrox + Lenvatinib in second-line HCC
  • Results & clinical experience from Phase 1b/2a study
  • Data in the context of current clinical practice in second-line HCC

Dr. Hong Jae Chon, CHA Bundang Hospital, Seoul, Korea

 

Fostrox + Lenvatinib moving forward.

Dr Pia Baumann, Chief Medical Officer, Medivir AB